The study by Anwar et al. evaluates the effectiveness of combining intralesional platelet-rich plasma (PRP) injections with methotrexate (MTX) in treating chronic plaque psoriasis, a common, chronic inflammatory skin disorder characterized by red, scaly plaques. Psoriasis affects approximately 2-3% of the population and is associated with systemic manifestations, including an increased risk of cardiovascular disease and psychological disorders such as depression.
This descriptive case series was conducted at the Department of Dermatology, Ammerudin Medical College, Lahore, involving 73 patients aged 18 to 60 years. The patients were treated over a 16-week period, during which they received both PRP and MTX. PRP was prepared from the patients' own blood through a two-stage centrifugation process. Injections were administered in psoriatic plaques at specific intervals, followed by weekly MTX injections for four weeks. This combination treatment aimed to leverage the regenerative properties of PRP alongside the anti-inflammatory effects of MTX.
The results were promising, with 82.19% of patients showing significant improvement, defined as a Psoriasis Area Severity Index (PASI) score reduction of ≥75% by the end of the study. The study found that combining PRP with MTX was more effective than traditional therapies alone, significantly improving plaque resolution and reducing the risk of systemic side effects associated with oral or systemic administration of MTX.
The study concludes that the combination of intralesional PRP and MTX offers a highly effective treatment option for chronic plaque psoriasis, with substantial improvements in PASI scores and overall patient satisfaction.
The use of PRP, particularly in combination with MTX, aligns with the objectives of Novastem's stem cell therapies by enhancing tissue regeneration and modulating immune responses. Both PRP and stem cell therapies aim to treat inflammatory conditions like psoriasis. The success of this combination therapy suggests that similar or even enhanced outcomes might be achieved with stem cell treatments, offering a potentially comprehensive approach to managing chronic inflammatory skin disorders.
- Mechanism of Action: PRP promotes healing by delivering growth factors that stimulate tissue regeneration, while MTX reduces inflammation by inhibiting DNA synthesis and lymphocyte proliferation, making the combination particularly effective in psoriasis management.
- Clinical Benefits: The combination therapy led to significant improvements in PASI scores, with most patients achieving substantial plaque resolution, highlighting its potential as an alternative to more traditional systemic therapies.
- Potential for Broad Application: The effectiveness of PRP combined with MTX in treating chronic plaque psoriasis suggests its potential utility in other chronic inflammatory conditions, possibly expanding its application in regenerative medicine.
PlateletRichPlasma #ChronicPlaquePsoriasis #Methotrexate #PASI #SkinRegeneration #Inflammation #StemCellTherapy
THE POWER BRINGS YOU BACK
The study by Anwar et al. evaluates the effectiveness of combining intralesional platelet-rich plasma (PRP) injections with methotrexate (MTX) in treating chronic plaque psoriasis, a common, chronic inflammatory skin disorder characterized by red, scaly plaques. Psoriasis affects approximately 2-3% of the population and is associated with systemic manifestations, including an increased risk of cardiovascular disease and psychological disorders such as depression.
This descriptive case series was conducted at the Department of Dermatology, Ammerudin Medical College, Lahore, involving 73 patients aged 18 to 60 years. The patients were treated over a 16-week period, during which they received both PRP and MTX. PRP was prepared from the patients' own blood through a two-stage centrifugation process. Injections were administered in psoriatic plaques at specific intervals, followed by weekly MTX injections for four weeks. This combination treatment aimed to leverage the regenerative properties of PRP alongside the anti-inflammatory effects of MTX.
The results were promising, with 82.19% of patients showing significant improvement, defined as a Psoriasis Area Severity Index (PASI) score reduction of ≥75% by the end of the study. The study found that combining PRP with MTX was more effective than traditional therapies alone, significantly improving plaque resolution and reducing the risk of systemic side effects associated with oral or systemic administration of MTX.
The study concludes that the combination of intralesional PRP and MTX offers a highly effective treatment option for chronic plaque psoriasis, with substantial improvements in PASI scores and overall patient satisfaction.
The use of PRP, particularly in combination with MTX, aligns with the objectives of Novastem's stem cell therapies by enhancing tissue regeneration and modulating immune responses. Both PRP and stem cell therapies aim to treat inflammatory conditions like psoriasis. The success of this combination therapy suggests that similar or even enhanced outcomes might be achieved with stem cell treatments, offering a potentially comprehensive approach to managing chronic inflammatory skin disorders.
PlateletRichPlasma #ChronicPlaquePsoriasis #Methotrexate #PASI #SkinRegeneration #Inflammation #StemCellTherapy